Nine-gene MPI can provide accurate survival stratification in patients with NSCLC
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease, according to a study published August 18 in the JNCI: Journal of the National Cancer Institute.
Non-small cell lung cancer (NSCLC) accounts for roughly 85% of all lung cancers, additionally; lung cancer is the leading cause of cancer death through out the world. While gene expression profiles have been shown to ...



